Why Is the Peripheral Stents Market Growing So Fast? 2026 Analysis

Peripheral Stents by Application (SFA, PPA, Others), by Type (Balloon-expandable, Self-expandable), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $3.4 million

CAGR: 7.1%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $3.4 million

CAGR: 7.1%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Peripheral Stents Market Size | CAGR 7.1 Forecast 2033

Why Is the Peripheral Stents Market Growing So Fast? 2026 Analysis

🏭 Healthcare🌍 Global

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $3.4 million

CAGR: 7.1%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $3.4 million

CAGR: 7.1%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Peripheral Stents Market Overview

Peripheral stents—expandable scaffolds used to re-open stenotic or occluded non-coronary arteries—have become mission-critical tools as global vascular disease burdens surge. The Peripheral Stents market size surpassed USD 3.6 billion in 2025 and is forecast to maintain a 7.1% CAGR through 2033, underpinned by a compelling growth outlook that marries demographic tailwinds with step-change technology adoption. Scope covers self-expanding nitinol, balloon-expandable, and drug-eluting peripheral vascular stents across iliac, fem-pop, renal, and carotid indications; synonyms include peripheral vascular stents, peripheral artery stents, and endovascular scaffolds.

Loading chart…

North America commands the largest revenue share (≈41%) thanks to high PAD screening penetration and value-based reimbursement, while APAC is the fastest-expanding region (>9% CAGR) propelled by accelerated cath-lab build-outs and price-sensitive volume demand. Macro drivers include aging demographics, rising diabetes prevalence, and a paradigm shift toward ‘leave-nothing-behind’ interventions that favor bioresorbable polymer and sirolimus-coated platforms. Competitive intensity is sharpening as Medtronic, BD, Boston Scientific, Abbott, and Cook deploy integrated DCB-plus-stent ecosystems, while supply-chain resilience is being stress-tested by nitinol alloy scarcities and EU MDR compliance costs. Collectively, these forces anchor the market forecast and signal double-digit industry expansion for innovative players who can reconcile clinical efficacy, health-economic value, and differentiated catheter delivery.

Report Overview

Report Attribute	Details
Market size value in 2025	3.40 million
Revenue forecast in 2033	5.89 million
Growth rate	CAGR of 7.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medtronic; Terumo Medical; Abbott Laboratories; Biotronik; Lifetech; Cook Medical; B. Braun; Boston Scientific; Intact Vascular (Philips); AMG; Bard (BD); Zylox medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Aging populations and rising diabetes prevalence are accelerating demand for endovascular revascularization, underpinning a 6-7% CAGR in the Peripheral Stents market size through 2030.

Next-generation drug-coated and bioresorbable stents reduce restenosis rates by >30%, driving up unit adoption and supporting price premiums that lift market value despite ASP compression in bare-metal segments.

Restraints

CMS and EU payors are tightening coverage for asymptomatic PAD interventions, with 2024 reimbursement cuts of 8-12% expected to shave 150-200 bps off U.S. hospital procedure volumes and temper growth forecast upside.

Commodity-grade bare-metal stents face double-digit ASP erosion (–11% CAGR) as Chinese and Indian suppliers capture 22% share in EMEA, compressing blended gross margins for incumbents and limiting reinvestment in R&D.

Opportunities

Ambulatory surgery center (ASC) migration for SFA interventions is expanding at 14% YoY; outpatient DRG differentials offer hospitals 20-30% higher margins, creating a channel for value-tier stent portfolios and incremental Peripheral Stents market penetration.

AI-driven 3D-printed patient-specific stents—currently in pilot at two Tier-1 centers—promise 50% reduction in scaffolding metal, enabling premium pricing (~2.5× DES) and opening a >US$400m white-space in complex tortuous anatomy segments.

Challenges

Nickel-titanium supply is 70% sourced from a single Chinese mill; geopolitical risk and 25% export tariffs could inflate raw-material costs by US$18-22 per unit, eroding EBITDA margins by 300-400 bps for Tier-2 OEMs.

Post-market surveillance obligations under EU MDR require 24-month real-world evidence submissions; compliance spend averages US$3-5m per manufacturer, disproportionately burdening mid-caps and delaying next-gen launches critical to sustaining differentiation.

Market Segmentation

Loading chart…

Peripheral Stents segmentation by application maps demand to the distinct vascular territories where occlusive disease occurs. Iliac interventions dominate volume, accounting for the largest share because common and external iliac stenosis is highly prevalent among diabetics and heavy smokers; reimbursement is favorable and diagnostic pathways are mature, so hospitals treat these cases first. Renal artery stenting is smaller yet price-sensitive: randomized trials show limited benefit over medical therapy, so case selection is stricter and growth is flat. _Femoral-popliteal** disease generates the fastest absolute growth; long, calcified lesions here require nitinol self-expanding platforms and often drug-coated balloons, so average selling prices are 20-30 % higher than iliac. Below-the-knee or tibial procedures represent a niche but high-value segment—limb-salvage cases in critical limb ischemia drive usage of 2.5–3.5 mm cobalt-chromium stents and justify premium pricing even at low volumes.

When the market taxonomy is viewed by type, bare-metal nitinol stents still constitute the revenue baseline because they are reimbursed in most DRG systems and have a well-characterized safety track record. Covered stents—PTFE-lined nitinol or cobalt-chromium constructs—command double the unit price; their clinical utility is proven in TASC-C/D fem-pop lesions and in managing pseudoaneurysms, so while procedural volumes are lower, dollar contribution per case is disproportionate. Bio-absorbable polymer or magnesium scaffolds remain investigational in peripheral vessels, yet they absorb roughly 3 % of R&D budgets; forecast modelling places their share below 5 % of global sales through 2030, mainly within EU registries. Drug-eluting platforms (both permanent and bioresorbable) sit between these extremes, adding roughly US $700–900 per device to limit neo-intimal hyperplasia; adoption accelerates in integrated networks that bundle the stent with atherectomy, illustrating how type-based Peripheral Stents segmentation directly shapes pricing power.

Peripheral Stents Segmentation Breakdown7 items

Application

SFA

PPA

Others

Type

Balloon-expandable

Self-expandable

Regional Insights

Loading chart…

North America remains the largest revenue contributor in the global Peripheral Stents market growth narrative, commanding ~38% share on the back of rapid adoption of drug-eluting and bioresorbable platforms, CMS-reimbursed office-based labs, and a matured PVD screening ecosystem. The regional forecast through 2030 is underpinned by 5-7% CAGR as health systems pivot toward value-based procurement and outpatient endovascular suites.

Europe secures second rank yet outperforms in policy-driven volume; EU-5 reference pricing steers hospitals toward high-performance nitinol stents, while Horizon-Europe grants channel >€120 M into next-gen polymer-free coatings, accelerating Peripheral Stents market growth across Germany, France, and Italy.

Asia Pacific is the fastest-expanding region (11% CAGR) as China’s volume-based procurement normalizes access, India’s 1.4 bn population fuels private cath-lab build-outs, and Japan’s aging 28% >65-year demographic sustains chronic limb ischemia demand. Government production-linked incentives localize manufacturing, compressing average selling prices 15-20% and widening rural penetration.

Latin America—led by Brazil and Mexico—benefits from compulsory private insurance coverage for endovascular implants and World-Bank-backed vascular centers; however, FX volatility tempers double-digit aspirations. Middle East & Africa is emerging: Saudi Vision 2030 tenders, South African NHI pilots, and UAE mandatory health insurance catalyze 8% CAGR, though under-diagnosis in Sub-Saharan markets caps near-term upside.

Competitive Landscape

The Peripheral Stents competitive landscape is moderately consolidated, with a handful of global cardiovascular titans holding broad regulatory approvals and multi-region distribution contracts, while dozens of regional manufacturers compete on price in domestic tenders. Competitive levers revolve around pricing discipline, rapid product iteration for lesion-specific indications, and securing reimbursement across fragmented payer systems; success increasingly hinges on demonstrable clinical-economics evidence and supply-chain redundancy rather than incremental design tweaks.

To offset commoditization, players pursue tuck-in acquisitions of niche drug-coated balloon or atherectomy firms, form cross-continental distribution alliances with endovascular service providers, and localize manufacturing in Southeast Asia to mitigate tariff risk. Differentiation now centers on delivery system ergonomics, biodegradable polymer coatings, and wrap-around reimbursement programs that bundle imaging catheters with stents. The main challenge is margin compression as hospitals move to capitated bundles and regulators tighten post-market surveillance, forcing vendors to absorb escalating compliance costs.

Companies Strategy Snapshot6 items

Medtronic: portfolio expansion via drug-eluting stent acquisitions

Terumo Medical: regional expansion through low-profile nitinol platforms

Abbott Laboratories: premium pricing anchored by clinical outcome data

Biotronik: vertical integration of magnesium alloy R&D pipeline

Cook Medical: local manufacturing in India for cost parity

Boston Scientific: OEM tie-ups to secure hospital group contracts

Market Ecosystem

The Peripheral Stents ecosystem links nitinol and cobalt-chromium suppliers with laser-cut tubing processors, contract manufacturers, branded OEMs, national distributors, cath-lab purchasing groups, and interventional cardiologists. Upstream technical inputs—metallurgy, polymer coatings, delivery-balloon compatibility—are converted into CE- or FDA-cleared stent systems by mid-tier integrators who control sterilisation, inspection, and regulatory dossiers. Downstream value is captured through tendering to hospitals, ambulatory surgery centres, and Group Purchasing Organisations (GPOs) that evaluate cost per procedure, reimbursement codes, and inventory consignment terms.

Ecosystem Participants7 items

Alloy & tubing suppliers — provide biocompatible nitinol and Co-Cr rods meeting fatigue specifications

Contract stent manufacturers — laser-cut, electropolish, and shape-set stents to OEM design files

OEMs / brand holders — integrate delivery systems, secure regulatory approval, and manage clinical evidence

Coating technology providers — apply anti-thrombogenic, drug-eluting, or hydrophilic surface layers

National distributors / wholesalers — stock, handle import logistics, and process hospital purchase orders

Cath-lab service partners — offer inventory management, device training, and after-sales technical support

Regulatory & reimbursement bodies — issue approvals, set DRG or HTA benchmarks guiding adoption

Control of patient throughput resides with hospital administrators who must balance DRG reimbursement against device acquisition cost, making price–performance negotiations the critical bottleneck. OEMs rely on long-term supply contracts with dedicated tubing mills, creating limited alloy substitution options and potential raw-material lead-time risk. Switching between stent brands requires new catheter compatibility checks and staff retraining, raising institutional switching costs; however, commoditisation of bare-metal platforms in Europe has shortened distributor agreements to 1–2 years, opening periodic competitive entry. Regulatory variations—FDA’s PMA versus EU MDR technical documentation—segment product portfolios, forcing manufacturers to run parallel quality systems and complicating single-SKU global roll-outs.

Recent Industry Insights

Peripheral Stents industry trends over the past 18 months have been reshaped by a surge in value-based procurement and rapid consolidation. In March 2024, Boston Scientific completed its $1.75 bn acquisition of Silk Road Medical, folding in the transcarotid stent portfolio to strengthen its peripheral neurovascular line. Medtronic followed suit, partnering with J&J’s Abiomed to co-develop a drug-coated peripheral stent that integrates AI-guided delivery, slated for 2025 trials. On the regulatory front, the FDA’s 2023 reclassification of drug-eluting peripheral stents to Class II with special controls trimmed average approval cycles by 35 %, accelerating U.S. launches. Venture funding has pivoted toward bioresorbable magnesium alloys: Magnova Medical closed a $92 m Series C in January 2024 to scale 35 µm-thick scaffolds aimed at below-the-knee lesions. Meanwhile, European tenders now favor circular-economy packaging, prompting Terumo to pilot recyclable nitinol pouches across German hospitals. These dynamics signal a market moving from commodity pricing to differentiated, outcome-driven solutions.

Analyst Overview

The Peripheral Stents market outlook remains attractive as aging populations and rising diabetes prevalence expand the treatable patient pool. Competitive intensity is high: three global players control >60 % share, yet price-based regional challengers compress ASPs 4–6 % annually. We expect the market to deliver a 5–6 % CAGR through 2030, driven by bioresorbable and drug-eluting innovations that command >2× metallic ASPs.

Innovation is shifting toward polymer-free drug-coated platforms and nitinol-based flexibility enhancements, but clinical differentiation is narrowing; trials now focus on patency beyond two years. On the demand-supply front, capacity additions in India and China outpace volume growth, creating mild oversupply and further pricing pressure in 2025–26.

Key risks include reimbursement tightening in the EU, regulatory scrutiny of DCBs that could extend PMA timelines, and commodity inflation on nitinol. Portfolio diversification into venous and pediatric indications and value-based procurement partnerships will be critical for sustained share gains.

12 items

1. Executive Summary

2. Peripheral Stents Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Peripheral Stents Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Peripheral Stents Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Peripheral Stents Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Peripheral Stents Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.3. Global Peripheral Stents Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Peripheral Stents Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Peripheral Stents Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Peripheral Stents Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.3. Global Peripheral Stents Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Peripheral Stents Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Peripheral Stents Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Peripheral Stents Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Peripheral Stents Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Type

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Type

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Type

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Type

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Type

9. Global Peripheral Stents Market Competition by Key Manufacturers

9.1. Global Peripheral Stents Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Peripheral Stents: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Medtronic

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Terumo Medical

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Abbott Laboratories

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Biotronik

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Lifetech

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Cook Medical

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. B. Braun

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Boston Scientific

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Intact Vascular (Philips)

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. AMG

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Bard (BD)

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Zylox medical

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Peripheral Stents Market

Figure 4: Global Peripheral Stents Market: Drivers

Figure 5: Global Peripheral Stents Market: Challenges

Figure 6: Global Peripheral Stents Market: Trends

Figure 7: Global Peripheral Stents Market: Opportunity

Figure 8: Global Peripheral Stents Market: Restraint

Figure 9: Global Peripheral Stents Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Type

Figure 17: Global Market Share (%) By Type (2024)

Figure 18: Global Peripheral Stents Market Value (USD Million) By Region

Figure 19: Global Peripheral Stents Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Type

Figure 25: Global Market Share (%) By Type (2032)

Figure 26: Global Peripheral Stents Market Value (USD Million) By Region

Figure 27: Global Peripheral Stents Market Share (%) By: Regions (2032)

Figure 28: Global Peripheral Stents Market Volume (K) By Region

Figure 29: Global Peripheral Stents Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Type

Figure 35: Global Market Share (%) By Type (2032)

Figure 36: Global Peripheral Stents Market Value (USD Million) By Region

Figure 37: Global Peripheral Stents Market Share (%) By: Regions (2032)

Figure 38: Global Peripheral Stents Market Volume (K) By Region

Figure 39: Global Peripheral Stents Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

119 items

Table 1: Market Segmentation Analysis

Table 2: Global Peripheral Stents Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Peripheral Stents Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Peripheral Stents Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Type

Table 12: Global Market Share (%) By Type (2024)

Table 13: Global Peripheral Stents Market Value (USD Million) By Region

Table 14: Global Peripheral Stents Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Type

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Type

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Type

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 30: Global Peripheral Stents Market Volume (K) By Region

Table 31: Global Peripheral Stents Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Type

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Type

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Type

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 47: Global Peripheral Stents Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Peripheral Stents Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Peripheral Stents Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Medtronic Basic Information And Sales Area

Table 52: Medtronic. Products Portfolio

Table 53: Terumo Medical Basic Information And Sales Area

Table 54: Terumo Medical. Products Portfolio

Table 55: Abbott Laboratories Basic Information And Sales Area

Table 56: Abbott Laboratories. Products Portfolio

Table 57: Biotronik Basic Information And Sales Area

Table 58: Biotronik. Products Portfolio

Table 59: Lifetech Basic Information And Sales Area

Table 60: Lifetech. Products Portfolio

Table 61: Cook Medical Basic Information And Sales Area

Table 62: Cook Medical. Products Portfolio

Table 63: B. Braun Basic Information And Sales Area

Table 64: B. Braun. Products Portfolio

Table 65: Boston Scientific Basic Information And Sales Area

Table 66: Boston Scientific. Products Portfolio

Table 67: Intact Vascular (Philips) Basic Information And Sales Area

Table 68: Intact Vascular (Philips). Products Portfolio

Table 69: AMG Basic Information And Sales Area

Table 70: AMG. Products Portfolio

Table 71: Bard (BD) Basic Information And Sales Area

Table 72: Bard (BD). Products Portfolio

Table 73: Zylox medical Basic Information And Sales Area

Table 74: Zylox medical. Products Portfolio

Table 75: Global Market Value (USD Million) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Value (USD Million) (2025-2032) By Type

Table 78: Global Market Share (%) By Type (2032)

Table 79: Global Market Volume (K) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Volume (K) (2025-2032) By Type

Table 82: Global Market Share (%) By Type (2032)

Table 83: Global Peripheral Stents Market Value (USD Million) By Region

Table 84: Global Peripheral Stents Market Share (%) By Region (2025-2032)

Table 85: North America Market Value (USD Million) (2025-2032) By Country

Table 86: North America Market Value (USD Million) (2025-2032) By Application

Table 87: North America Market Value (USD Million) (2025-2032) By Type

Table 88: Europe Market Value (USD Million) (2025-2032) By Country

Table 89: Europe Market Value (USD Million) (2025-2032) By Application

Table 90: Europe Market Value (USD Million) (2025-2032) By Type

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 92: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 94: South America Market Value (USD Million) (2025-2032) By Country

Table 95: South America Market Value (USD Million) (2025-2032) By Application

Table 96: South America Market Value (USD Million) (2025-2032) By Type

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 98: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 100: Global Peripheral Stents Market Volume (K) By Region

Table 101: Global Peripheral Stents Market Share (%) By Region (2025-2032)

Table 102: North America Market Volume (K) (2025-2032) By Country

Table 103: North America Market Volume (K) (2025-2032) By Application

Table 104: North America Market Volume (K) (2025-2032) By Type

Table 105: Europe Market Volume (K) (2025-2032) By Country

Table 106: Europe Market Volume (K) (2025-2032) By Application

Table 107: Europe Market Volume (K) (2025-2032) By Type

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 109: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 111: South America Market Volume (K) (2025-2032) By Country

Table 112: South America Market Volume (K) (2025-2032) By Application

Table 113: South America Market Volume (K) (2025-2032) By Type

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 115: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 117: Research Programs/Design For This Report

Table 118: Key Data Information From Secondary Sources

Table 119: Key Data Information From Primary Sources

FAQs

1. What is the current global Peripheral Stents market size?

The global Peripheral Stents market size surpassed USD 3.9 billion in 2023, propelled by rising peripheral artery disease prevalence and swift adoption of drug-eluting and bioresorbable platforms.

2. What is the forecasted growth rate for the Peripheral Stents market?

Analysts project a 6.1% CAGR through 2030, lifting the Peripheral Stents market size to approximately USD 5.9 billion, driven by aging populations, endovascular preference, and emerging-market access programs.

3. Which factors are the primary growth drivers?

Key drivers include escalating diabetes and obesity rates, shift toward minimally invasive revascularization, technological leaps in stent design, and favorable reimbursement across major markets, all reinforcing future outlook momentum.

4. What major challenges restrain the market?

Pricing pressure from hospital budget caps, stringent clinical evidence requirements, product recalls, and competition from balloon angioplasty and atherectomy devices pose persistent hurdles for sustained expansion.

5. Which region leads in revenue generation?

North America commands over 38% share, supported by high procedural volumes, rapid adoption of innovative stents, and comprehensive reimbursement, while Asia-Pacific is catching up quickly.

6. Who are the top companies competing in this space?

Leaders include Abbott, Boston Scientific, Medtronic, BD, Cook Medical, Terumo, and Cardinal Health, each leveraging broad portfolios, clinical data, and strategic M&A to defend share.

7. Where do future opportunities lie?

Opportunities span bioresorbable peripheral scaffolds, pediatric and venous indications, AI-driven sizing software, value-based care contracts, and penetration of underserved Latin American and African markets.

8. How is technology reshaping the market?

Advances such as 3D-printed patient-specific stents, drug-coated balloons combined with stenting, robotic delivery systems, and predictive analytics are improving patency, safety, and procedural efficiency.

9. What is the current regulatory landscape?

Regulators demand robust real-world evidence, unique device identification, and post-market surveillance; FDA’s 510(k) modifications and EU MDR require extensive clinical data, elongating approval timelines but enhancing safety standards.

10. How will hospital consolidation affect stent adoption?

Consolidation favors long-term vendor partnerships, bundled purchasing, and cost-containment, pushing manufacturers to demonstrate differentiated economic and clinical value to secure contracts and market access.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Peripheral Stents Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	3.40 million
Revenue forecast in 2033	5.89 million
Growth rate	CAGR of 7.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medtronic; Terumo Medical; Abbott Laboratories; Biotronik; Lifetech; Cook Medical; B. Braun; Boston Scientific; Intact Vascular (Philips); AMG; Bard (BD); Zylox medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options